Shots:
- Mestag to receive option fees, milestones, royalties and will deploy its specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets
- Janssen to get an option to exclusive license to develop and commercialize therapies directed against up to two targets emerges from the collaboration
- Apart form this collaboration, Mestag will continue to develop its inflammatory disease and cancer programs as it progresses its pipeline of first-in-class therapeutics towards the clinic
Click here to read full press release/ article | Ref: Mestag Therapeutics | Image: Mestag Therapeutics
The post Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease first appeared on PharmaShots.
